Natural killer T cell-mediated antitumor immune responses and their clinical applications (Q36521991)

14 August 2017

1 reference

title

Natural killer T cell-mediated antitumor immune responses and their clinical applications (English)

1 reference

14 August 2017

5

Masaru Taniguchi

1 reference

14 August 2017

Ken-ichiro Seino

1

1 reference

14 August 2017

Shinichiro Motohashi

series ordinal

2

1 reference

14 August 2017

Takehiko Fujisawa

series ordinal

3

1 reference

14 August 2017

Toshinori Nakayama

series ordinal

4

1 reference

14 August 2017

29 June 2006

1 reference

14 August 2017

1 reference

14 August 2017

97

1 reference

14 August 2017

807-812

1 reference

14 August 2017

9

1 reference

NKT cells: what's in a name?

14 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

The regulatory role of Valpha14 NKT cells in innate and acquired immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

The crystal structure of human CD1d with and without alpha-galactosylceramide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Mechanism of CD1d-restricted natural killer T cell activation during microbial infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Differential tumor surveillance by natural killer (NK) and NKT cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Murine CD1d-restricted T cell recognition of cellular lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Lysosomal glycosphingolipid recognition by NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Differential antitumor immunity mediated by NKT cell subsets in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Functionally distinct NKT cell subsets and subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Loss of IFN-gamma production by invariant NK T cells in advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00257.X

10.1111/J.1349-7006.2006.00257.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference